Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related DiseaseMarketBeat · 3 days ago
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceGlobeNewsWire · Oct 15, 2026
Russian plague outbreak could boost these under-the-radar pharma stocksInvezz · Oct 5, 2026
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 3, 2026
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 2, 2026Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.17 | -$0.16 | Beat |
| May 13, 2026 | -$0.18 | -$0.13 | Beat |
| Mar 26, 2026 | -$0.20 | $0.53 | Beat |
| Nov 13, 2025 | -$0.25 | -$0.13 | Beat |
| Aug 12, 2025 | -$0.38 | -$0.03 | Beat |
| May 13, 2025 | -$0.55 | -$0.25 | Beat |